Article Text

Download PDFPDF
Hearing outcome of infants with congenital cytomegalovirus and hearing impairment
  1. Efraim Bilavsky1,2,
  2. Keren Shahar-Nissan1,2,
  3. Joseph Pardo2,3,
  4. Joseph Attias4,5,
  5. Jacob Amir1,2
  1. 1Department of Pediatrics C, Schneider Children's Medical Center, Petah Tiqva, Israel
  2. 2Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
  3. 3Department of Gynecology and Obstetrics, Rabin Medical Center, Beilinson Hospital, Petah Tiqva, Israel
  4. 4Institute of Audiology and Clinical Neurophysiology, Schneider Children's Medical Center, Petah Tiqva, Israel
  5. 5Department of Communication Sciences & Disorders, University of Haifa, Haifa, Israel
  1. Correspondence to Dr Efraim Bilavsky, Department of Pediatrics C, Schneider Children's Medical Center of Israel, Petah Tiqva 49202, Israel; yoji{at}


Background Congenital cytomegalovirus (cCMV) is the most common non-genetic cause of childhood sensorineural hearing loss. Antiviral treatment has been shown to prevent hearing deterioration in these infants. However, studies focused on infants with hearing impairment at birth and on the specific degree of impairment and further improvement or deterioration are lacking.

Objective To investigate the relationship between hearing status at birth and any change in hearing status at the end of a prolonged follow-up period, after receiving 12 months of antiviral treatment in children born with hearing impairment due to congenital cCMV.

Methods Clinical, laboratory, radiological and audiological data of all infants with cCMV infection followed in our centre between 2005 and 2013 were reviewed. Treatment with antiviral medication for hearing impairment found during the neonatal period was12 months of gan/valganciclovir. Hearing studies were performed only on infants who had been followed up for more than 1 year after treatment.

Results Hearing impairment at birth was found in 54 (36.2%) of the 149 infants diagnosed with symptomatic cCMV, and found in 77 affected ears; unilateral in 31 (57.4%) and bilateral in 23 (42.6%). After 1 year of antiviral treatment and a long-term follow-up of the 77 affected ears at baseline, 50 (64.9%) had improved, 22 (28.6%) remained unchanged and 5 (6.5%) had deteriorated. Most improved ears (38/50=76%) returned to normal hearing. Improvement was most likely to occur in infants born with mild or moderate hearing loss and less in those with severe impairment.

Conclusions We found that infants born with cCMV and hearing impairment, receiving 12 months of antiviral treatment, showed significant improvement in hearing status. The probability of hearing improvement seems inversely related to the severity of the impairment at birth.

  • Audiology
  • Congenital Abnorm

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles

  • Atoms
    Nick Brown